According to the results of the independent evaluation of the company “Darnitsa” is estimated at more than $ 400 million.
In an interview with Liga.net the head of the Board of Directors Darnitsa Group Dmytro shymkiv.
According to Shymkiv, the share of the Ukrainian market of FarmFirma Darnitsa in packages (units of production, – an edition) – 14%.
“This means that we are the biggest pharmaceutical manufacturer in Ukraine. Next, the company holds 7%”, – said schimke.
He noted that the market multiples in the assessment of the global pharmaceutical business above the average multipliers for other sectors significantly.
For example, when it comes to the purchase of the business of generic companies, average EBITDA multiples are X 10.
“There are transactions with a multiplier of 27-28. For example, the acquisition of the company by Shire company Takeda is estimated at 81 billion dollars. In Europe in recent years and the consolidation of Pharma, and so preparing a lot of deals,” said shymkiv.
According to him, the market multiples of the Ukrainian pharmaceutical business, on average, 8 to 10, depending on the company’s portfolio.
Pharmaceutical firm “Darnitsa” was founded in 1930. The company’s portfolio includes about 250 names of drugs.
In 2017, the net profit amounted to Darnitsa 342,1 million UAH.
Beneficiaries of the company is a family zagori, including the Deputy of the Verkhovna Rada of the last convocation Gleb zagoriy.